471
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

Phenotypic synergy testing of ceftazidime–avibactam with aztreonam in a university hospital having high number of metallobetalactamase producing bacteria

, , , , ORCID Icon &
Pages 801-807 | Received 20 Apr 2020, Accepted 22 Jun 2020, Published online: 06 Jul 2020

References

  • Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. Biomed Res Int. 2016;2016:2475067.
  • Mohanty S, Gajanand M, Gaind R. Identification of carbapenemase-mediated resistance among Enterobacteriaceae bloodstream isolates: a molecular study from India. Indian J Med Microbiol. 2017;35(3):421–425.
  • Shirley M. Ceftazidime-avibactam: a review in the treatment of serious Gram-negative bacterial infections. Drugs. 2018;78(6):675–692.
  • Rawat D, Nair D. Extended-spectrum β-lactamases in Gram negative bacteria. J Glob Infect Dis. 2010;2(3):263–274.
  • Marshall S, Hujer AM, Rojas LJ, et al. Can Ceftazidime–Avibactam and Aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017;61(4):e02243.
  • Exner M, Bhattacharya S, Christiansen B, et al. Antibiotic resistance: what is so special about multidrug-resistant Gram-negative bacteria? GMS Hyg Infect Control. 2017;12:Doc05.
  • Clinical and Laboratory Standards Institute. M100 Performance standards for antimicrobial susceptibility testing. 29th ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2010.
  • van den Bijllaardt W, Janssens MM, Buiting AG, et al. Extended-spectrum β-lactamase (ESBL) polymerase chain reaction assay on rectal swabs and enrichment broth for detection of ESBL carriage. J Hosp Infect. 2018;98(3):264–269.
  • Lee TD, Adie K, McNabb A, et al. Rapid detection of KPC, NDM, and OXA-48-like carbapenemases by real-time PCR from rectal Swab surveillance samples. J Clin Microbiol. 2015;53(8):2731–2733.
  • Manoharan A, Chatterjee S, Mathai D, SARI Study Group. Detection and characterization of metallo beta lactamases producing Pseudomonas aeruginosa. Indian J Med Microbiol. 2010;28(3):241–244.
  • Rolain JM, Kempf M, Leangapichart T, et al. Plasmid-mediated mcr-1 gene in colistin-resistant clinical isolates of Klebsiella pneumoniae in France and Laos. Antimicrob Agents Chemother. 2016; 60(11):6994–6995.
  • Laishram S, Pragasam A, Bakthavatchalam YD, et al. An update on technical, interpretative and clinical relevance of antimicrobial synergy testing methodologies. Indian J Med Microbiol. 2017;35(4):445–468.
  • Sopirala MM, Mangino JE, Gebreyes WA, et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54(11):4678–4683.
  • Wenzler E, Deraedt MF, Harrington AT, et al. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens. Diagn Microbiol Infect Dis. 2017;88(4):352–354.
  • Pragasam AK, Veeraraghavan B, Shankar BA, et al. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-like producing organisms: lessons learnt from in vitro study. Indian J Med Microbiol. 2019;37(1):34–41.
  • Masuda N, Sakagawa E, Ohya S, et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2000;44(12):3322–3327.
  • Periasamy H, Joshi P, Palwe S, et al. High prevalence of Escherichia coli clinical isolates in India harbouring four amino acid inserts in PBP3 adversely impacting activity of aztreonam/avibactam. J Antimicrob Chemother. 2020;75(6):1650–1651.
  • Sader HS, Mendes RE, Pfaller MA, et al. Antimicrobial activities of Aztreonam–Avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates. Antimicrob Agents Chemother. 2017; 62(1):e01856.
  • Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661–673.
  • Stone GG, Newell P, Gasink LB, et al. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme . J Antimicrob Chemother. 2018;73(9):2519–2523.
  • Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE); a randomized, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18(3):285–295.
  • Davido B, Fellous L, Lawrence C, et al. Ceftazidime–Avibactam and Aztreonam, an interesting strategy to overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61(9):e01008.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.